Insmed Incorporated
Clinical trials sponsored by Insmed Incorporated, explained in plain language.
-
New drug brensocatib now available for bronchiectasis patients who completed key trial
Disease control APPROVED_FOR_MARKETINGThis program provides early access to brensocatib for people with non-cystic fibrosis bronchiectasis who finished the ASPEN study. The drug aims to control lung symptoms and reduce flare-ups. Participants must have taken brensocatib before and not had serious side effects related…
Sponsor: Insmed Incorporated • Aim: Disease control
Last updated May 26, 2026 08:40 UTC
-
New hope for PAH patients: Long-Term inhaler study underway
Disease control OngoingThis study looks at the long-term safety and tolerability of an inhaled powder called treprostinil palmitil (TPIP) for people with pulmonary arterial hypertension (PAH). Participants who completed earlier TPIP studies can join and continue treatment. The main goal is to track sid…
Phase: PHASE2, PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated May 26, 2026 08:30 UTC
-
New hope for painful skin condition: drug trial targets Flare-Ups
Disease control OngoingThis study tests an experimental drug called brensocatib in 214 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes boils and abscesses. Participants receive either the drug or a placebo for 16 weeks to see if it reduces inflammatory…
Phase: PHASE2 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated May 20, 2026 11:55 UTC